Why Annexon, Inc.’s (ANNX) Stock Is Up 6.18%
As of Monday, September 28, Annexon, Inc.’s ANNX share price has surged by 6.18%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Commentary & Analysis
Why Annexon, Inc.’s (ANNX) Stock Is Down 5.50%
As of Wednesday, September 23, Annexon, Inc.’s ANNX share price has dipped by 5.50%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Annexon, Inc.’s (ANNX) Stock Is Down 5.05%
As of Friday, August 28, Annexon, Inc.’s ANNX share price has dipped by 5.05%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Annexon, Inc.’s (ANNX) Stock Is Up 6.18%
As of Friday, August 21, Annexon, Inc.’s ANNX share price has surged by 6.18%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Annexon, Inc.’s (ANNX) Stock Is Up 5.04%
As of Thursday, July 30, Annexon, Inc.’s ANNX share price has surged by 5.04%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | ANNX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $801.9 | $257.1 | 43% |
|
| Shares Out (Mil) | 201.0 | 54.0 | 76% |
|
| Institutional Ownership | 99.0% | 93.2% | 84% |
|
| Float (Mil) | 163.8 | 41.3 | 70% |
|
| Beta | 1.21 | 0.95 | 71% |
|
| Avg Daily Volume (000s) | 3,539 | 728 | 87% |
|
| Price Change (52-week) |
35.6% | 50.6% | 78% |
|
| Growth | ANNX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.8% | na |
|
| Net Income (5yr) | (26.7%) | (10.1%) | 16% |
|
| EPS (5yr) | 20.2% | 15.7% | 69 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (44.0%) | (15.7%) | 9% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 6 | |
| Current EPS | ($0.280) | ($1.051) | ($1.087) | |
| Month Ago EPS | ($0.278) | ($1.050) | ($1.085) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.252) | ($0.982) | ($0.923) | |
| Year/Year Chg | 1.8% | (21.9%) | (82.8%) | |
| Financials | ANNX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($203) | ($44) | 7% |
|
| EPS (TTM) | ($1.127) | ($1.600) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($193) | ($33) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $67 | $2 | 73% |
|
| Long-Term Debt (Q1) (Mil) | $22 | $4 | 33% |
|
| Enterprise Value (Q1) (Mil) | $617 | $173 | 36% |
|
| Valuation | ANNX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.95 | 2.52 | 74% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ANNX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.2% | na |
|
| Net Margin | na | (73.7%) | na |
|
| ROA | (79.4%) | (47.7%) | 7% |
|
| ROE | (105.3%) | (54.9%) | 9% |
|
| Liabilities to Assets | 24.4% | 29.0% | 16% |
|
| F-Score | 1 | 3 | 1% |
|
Annexon, Inc. did not pass any screens on 9/30/2026.
